Healthy
Conditions
Brief summary
This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making.
Detailed description
This study will combine functional magnetic resonance imaging (fMRI), non-invasive transcranial magnetic stimulation (TMS), olfactory stimuli, and a devaluation task to define the specific contributions of orbitofrontal cortex (OFC) networks in outcome-guided behavior. We will use network-targeted TMS to modulate activity within anterior OFC and posterior OFC networks, examining if they have different contributions to decision-making. This is a randomized, between-subjects design.
Interventions
DEVICEReal transcranial magnetic stimulation (TMS) before conditioning
Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.
DEVICEReal transcranial magnetic stimulation (TMS) before devaluation test
Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.
Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.
Sponsors
Northwestern University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between 18 and 40 years old * Right-handed * Fluent English speakers
Exclusion criteria
* History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.) * History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, substance use disorder, etc.) * Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.) * Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.) * Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.) * Smell or taste dysfunction * History of significant allergies requiring hospitalization for treatment * History of severe asthma requiring hospitalization for treatment * Habitual smoking * History of eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, etc.) * Dieting or fasting * Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.) * Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.) * History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers * Claustrophobia * Pregnancy * Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.) * Use of medications that increase the likelihood of seizures (e.g., bupropion SR, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.) * History of surgical procedures performed on the brain or spinal cord * History of severe head trauma followed by loss of consciousness * History of fainting spells or syncope * Hearing problems or tinnitus
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Behavior on devaluation task | 1 hour after intervention | Percentage of cues predicting non-devalued vs devalued odors chosen during the devaluation task. |
| Resting-state functional magnetic resonance imaging | 1 hour after intervention | Resting-state activity determined by functional magnetic resonance imaging. |
Countries
United States
Contacts
Primary ContactChristina Zelano, PhD
Backup ContactGreg Lane, PhD
Outcome results
None listed